Clinical Autonomic Research

, Volume 14, Issue 6, pp 363–368 | Cite as

Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure

  • David S. Goldstein
  • Courtney Holmes
  • Horacio Kaufmann
  • Roy Freeman



Oral L-threo-3,4-dihydroxyphenylserine (L-DOPS), a synthetic catechol amino acid, increases standing blood pressure and improves standing ability in patients with neurogenic orthostatic hypotension, by conversion of L-DOPS to norepinephrine (NE) outside the brain. This study assessed the pharmacokinetics of L-DOPS, NE, and dihydroxyphenylglycol (DHPG), the main neuronal metabolite of NE, in patients with primary chronic autonomic failure from pure autonomic failure (PAF) or multiple system atrophy (MSA).


In 5 MSA and 4 PAF patients, antecubital venous blood was drawn during supine rest and plasma levels of catechols measured at various times for 48 hours after a single oral dose of 400 mg of L-DOPS.


Plasma L-DOPS peaked at 1.9 µg/ml (9 µmol/L) about 3 hours after drug administration, followed by a monoexponential decline with a half-time of 2–3 hours in both patient groups. Plasma NE and DHPG also peaked at about 3 hours, but at much lower concentrations (4 and 42 nmol/L). Compared to the MSA group, the PAF group had a smaller calculated volume of distribution of L-DOPS and up to 10-fold lower plasma NE levels at all time points. Plasma NE was above baseline in MSA even at 48 hours after L-DOPS.


The relatively long half-time for disappearance of L-DOPS compared to that of NE explains their very different attained plasma concentrations. The similar NE and DHPG responses in PAF and MSA suggests production of NE from LDOPS mainly in non-neuronal cells. Persistent elevation of plasma NE in MSA suggests residual release of NE from sympathetic nerves.

Key words

DOPS norepinephrine dihydroxyphenylglycol autonomic failure sympathetic nervous system 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R (2003) Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation 108:724–7283PubMedGoogle Scholar
  2. 2.
    Goldstein DS, Polinsky RJ, Garty M, Robertson D, Brown RT, Biaggioni I, Stull R, Kopin IJ (1989) Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 26:558–563PubMedGoogle Scholar
  3. 3.
    Polinsky RJ, Kopin IJ, Ebert MH, Weise V (1981) Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 31:1–7PubMedGoogle Scholar
  4. 4.
    Ziegler MG, Lake CR, Kopin IJ (1977) The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 296:293–297PubMedCrossRefGoogle Scholar
  5. 5.
    Mathias CJ (1995) The classification and nomenclature of autonomic disorders—ending chaos, resolving conflict and hopefully achieving clarity. Clin Auton Res 5:307–310PubMedGoogle Scholar
  6. 6.
    Holmes C, Eisenhofer G, Goldstein DS (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatog B Biomed Applic 653:131–138Google Scholar
  7. 7.
    Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22:429–436PubMedGoogle Scholar
  8. 8.
    Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36:739–744PubMedGoogle Scholar
  9. 9.
    Kempster PA, Frankel JP, Bovingdon M, Webster R, Lees AJ, Stern GM (1989) Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52:718–723PubMedCrossRefGoogle Scholar
  10. 10.
    Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A (1993) Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson’s disease. Neurology 43:367–371PubMedGoogle Scholar
  11. 11.
    Goldstein D, Horwitz D, Keiser HR, Polinsky RJ, Kopin IJ (1983) Plasma l-[3H]norepinephrine, d-[14C]norepinephrine, and d,l-[3H]isoproterenol kinetics in essential hypertension. J Clin Invest 72:1748–1758PubMedGoogle Scholar
  12. 12.
    Grossman E, Chang PC, Hoffman A, Tamrat M, Kopin IJ, Goldstein DS (1991) Tracer norepinephrine kinetics: dependence on regional blood flow and the site of infusion. Am J Physiol 260:R946–R952PubMedGoogle Scholar
  13. 13.
    Goldstein DS, Holmes C, Cannon RO III, Eisenhofer G, Kopin IJ (1997) Sympathetic cardioneuropathy in dysautonomias. N Engl J Med 336:696–702PubMedGoogle Scholar
  14. 14.
    Jennings G, Korner P, Willett I, Dudley F, Hasking G, Anderson W, Lambert G (1988) Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11:3–20PubMedGoogle Scholar
  15. 15.
    Crout JR, Sjoerdsma A (1964) Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 43:94–102PubMedGoogle Scholar
  16. 16.
    Spector S, Tarver J, Berkowitz B (1972) Effects of drugs and physiological factors in the disposition of catecholamines in blood vessels. Pharmacol Rev 24:191–202PubMedGoogle Scholar
  17. 17.
    Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676PubMedGoogle Scholar
  18. 18.
    Cannon WB (1939) A law of denervation. Am J Med Sci 198:737–750CrossRefGoogle Scholar
  19. 19.
    Davies B, Sudera D, Sagnella G, Marchesi-Saviotti E, Mathias C, Bannister R, Sever P (1982) Increased numbers of alpha receptors in sympathetic denervation supersensitivity in man. J Clin Invest 69:779–784CrossRefPubMedGoogle Scholar

Copyright information

© Steinkopff Verlag 2004

Authors and Affiliations

  • David S. Goldstein
    • 1
    • 2
  • Courtney Holmes
    • 1
  • Horacio Kaufmann
    • 3
  • Roy Freeman
    • 4
  1. 1.Clinical Neurocardiology SectionNational Institute of Neurological Disorders and Stroke National Institutes of HealthBethesda (MD)USA
  2. 2.NINDS, NIH, 10 Center Drive MSC-1620 Building 10 Room 6N252Bethesda (MD)USA
  3. 3.Mount Sinai School of MedicineNew York (NY)USA
  4. 4.Beth Israel Deaconess Medical CenterBoston (MA)USA

Personalised recommendations